Michael Burnstine, MD
Ophthalmology · Los Angeles, CANPI 1568478402
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $3,963 of the $5,309 with a category attached, or 74.6%. Poriferous LLC accounts for 74.6% of it on its own, with 7 other manufacturers making up the rest.
Across 58 payments — averaging $91.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Poriferous LLC$4K
- Amgen$703
- Alcon$243
- Merz North America, Inc.$168
- AbbVie$140
- Merz Pharmaceuticals, LLC$41
- plus $53 from 2 others
What the payments were for
- Royalty or licence$3,96375%
- Food & beverage$1,32925%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Poriferous LLC | 7 | $3,963 |
| Amgen(2 entities) | 41 | $703 |
| Alcon | 2 | $243 |
| Merz North America, Inc. | 3 | $168 |
| AbbVie | 2 | $140 |
| Merz Pharmaceuticals, LLC | 1 | $41 |
| Tarsus Pharmaceuticals, Inc. | 1 | $36 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Su-Por Surgical Implants$2,993
- Su-Por$727
- SuPor Surgical Implants$243
- TEPEZZA$150
- Hydrus Microstent$135
- Clareon$108
- XEOMIN$106
How this compares
$5,309 in reported general payments places this provider in the 75th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 185 | $1,604 |
| Prednisolone Acetate | 57 | $1,529 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 79 | $999 |
| Methylprednisolone | 124 | $738 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 15 | $508 |
| Fluticasone Propionate | 50 | $460 |
| Cephalexin | 99 | $425 |
| Tramadol Hcl | 86 | $87 |
| Ciprofloxacin Hcl | 14 | $55 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Los Angeles
- Andrew MoshfeghiLos Angeles$895K
- Barry SeibelLos Angeles$835K
- Nicole FramLos Angeles$551K
- Neda ShamieLos Angeles$547K
- David BoyerLos Angeles$406K
- David HamiltonLos Angeles$359K
- Arjan HuraLos Angeles$306K
- Firas RahhalLos Angeles$264K
- Kouros NourimahdaviLos Angeles$258K
- Daniel RootmanLos Angeles$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.